<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386839</url>
  </required_header>
  <id_info>
    <org_study_id>SHP607-201</org_study_id>
    <secondary_id>2014-003556-31</secondary_id>
    <nct_id>NCT02386839</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)</brief_title>
  <acronym>PEDAL</acronym>
  <official_title>Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the long-term efficacy and safety outcomes
      following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study
      ROPP-2008-01 (Section D) (NCT01096784).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2015</start_date>
  <completion_date type="Anticipated">August 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Visual Acuity as Assessed by an age-Appropriate Method</measure>
    <time_frame>6 months to 5.5 years corrected age (CA)</time_frame>
    <description>Visual acuity is a measure of how well a participant sees at different distances. It will be categorized as the following: normal (measurable acuity greater than or equal to [&gt;=] 20/40); below normal (20/200 less than or equal to [&lt;=] measurable acuity &lt;20/40); poor (measurable acuity &lt;=20/200); blind/low vision (only the ability to detect the 2.2 centimetre [cm] wide stripes on the low-vision Teller acuity card and at any location in the visual field).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Alignment Assessed by Corneal Light Reflex and by the Cover Test</measure>
    <time_frame>12 months to 5.5 years (CA)</time_frame>
    <description>Ocular alignment will be assessed in primary gaze by comparing the position of the corneal light reflection in left eye (OS) and right eye (OD) (corneal light reflection assessment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oculomotor Examination (Motility) Assessed by Corneal Light Reflex and by the Cover Test</measure>
    <time_frame>12 months to 5.5 years (CA)</time_frame>
    <description>Ocular motility refers to eye movements, which are governed by the 6 extraocular muscles in each eye. It will be assessed by examiner observation of the participant's ability to abduct, adduct, supra, and inferoduct each eye (to assess for strabismus).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Nystagmus</measure>
    <time_frame>12 months to 5.5 years (CA)</time_frame>
    <description>Nystagmus will be observed during the ocular alignment assessments. Presence or absence of nystagmus will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Refraction as Assessed by Retinoscopy With Cycloplegia</measure>
    <time_frame>6 months (CA)</time_frame>
    <description>Refraction is a measure of the lens power required for a focused image on the retina. Refraction with cycloplegia will be measured and recorded in diopters for each eye individually (OS and OD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stereoacuity</measure>
    <time_frame>5.5 years (CA)</time_frame>
    <description>Stereoacuity is a measure of depth perception and will be assessed using the Lang Stereotest. The presence or absence of stereopsis will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline to 5.5 years (CA)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight Z-score</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
    <description>Body weight will be assessed to the nearest 0.1 kilogram (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Length Z-score</measure>
    <time_frame>6 to 24 months (CA)</time_frame>
    <description>Body length (supine measurement) will be collected when participants are 24-months CA or younger. Body length will be measured by placing the participant in his or her back lying straight and the shoulders and buttocks are flat against the measuring surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Height Z-score</measure>
    <time_frame>5.5 years</time_frame>
    <description>Height will be collected when participants are older than 24-months CA using a stadiometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Head Circumference Z-score</measure>
    <time_frame>6 to 24 months (CA)</time_frame>
    <description>Head circumference or occipital frontal circumference will be measured over the occiput and just above the supraorbital ridge, which is the largest circumference of the head using a &quot;lasso&quot;-type, non-stretchable measuring tape such as the Lasso-o tape.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Development as Assessed by Bayley Scales of Infant and Toddler Development (BSID-III)</measure>
    <time_frame>12 to 24 months (CA)</time_frame>
    <description>The BSID-III will be used to assess cognitive, motor, and language skills, and is applicable to children aged 1-42 months. The BSID-III is an assessment tool designed to measure a young child's skills in the 3 core areas of development: cognitive, language, and motor. There are 5 subscales, the cognitive subscale (Score range: 55-145) stands alone while the 2 language subscales (expressive and receptive) combine to make a total language score (Range: 47-153) and the 2 motor subtests (fine and gross motor) form a combined motor scale (Range: 46-154). A positive value indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Development as Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI)</measure>
    <time_frame>5.5 years (CA)</time_frame>
    <description>The WPPSI is a measure of general cognitive development in children that has components of both verbal and nonverbal tasks. It is applicable to preschoolers and young children aged 2 years +6 months to 7 years +7 months, and is a direct assessment of a child's cognitive skills. The standard score For the WPPSI ranges from Below 70 (extremely low) to above 130 (very superior).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Development as Assessed by Physical Examination</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
    <description>Physical examinations will include a review of the participant's general appearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Development as Assessed by Neurological Examination for Assessment of Cerebral Palsy</measure>
    <time_frame>24 month (CA)</time_frame>
    <description>Comprehensive neurological examination for the diagnosis of cerebral palsy (CP) will be conducted. The Amiel-Tison neurological examination framework will be utilized for this assessment and will be conducted by trained medical professionals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Development as Assessed by Hearing Assessment</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
    <description>Results of previously completed hearing assessments will be recorded at the 6-month CA and 5-year CA visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behaviour as Assessed by Vineland Adaptive Behaviour Scales (VABS-II)</measure>
    <time_frame>6 months to 5.5 years (CA)</time_frame>
    <description>The VABS-II Expanded Interview Form will be used to measure the personal and social skills of participants serially over time; these scales are organized within a 3-domain structure: Communication, Daily Living, and Socialization. In addition, the VABS-II offers a Motor Skills Domain and an optional Maladaptive Behavior Index. The VABS-II Expanded Interview Form assesses what a participant actually does, rather than what he or she is able to do. The domain score ranges from 20 (low) to 140 (high). The mean of all 5 domains is 100 and standard deviation 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behaviour as Assessed by Child Behaviour Checklist (CBCL)</measure>
    <time_frame>24 months to 5.5 years (CA)</time_frame>
    <description>The CBCL (1 ½ to 5) is a parent-reported outcome measure used to assess behavioral, emotional, and social functioning of toddlers and preschool children aged 18-60 months. It is composed of 99 items that are rated on a Likert scale and includes the following 7 syndrome scales arranged under 2 domains (that is, Internalizing and Externalizing Problems): Internalizing Problems; Emotionally Reactive; Anxious/Depressed; Somatic Complaints; Withdrawn; Sleep Problems; Attention Problems; Aggressive Behavior. The scores range from 23 to 100. For the Total Problem, Internalization, and Externalization Scales, scores of less than 60 are considered non-clinical, 60-63 are borderline, and 64 or more are considered clinical. For all syndrome scales, scores of 65 or less are considered non-clinical, 66 through 70 are considered borderline, and 71 or greater are considered clinical.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behaviour as Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS)</measure>
    <time_frame>5.5 years (CA)</time_frame>
    <description>The ADHD-RS measures the behaviors of children with Attention-Deficit/Hyperactivity Disorder (ADHD). It consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-IV criteria. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items are grouped into 2 subscales: hyperactivity-impulsivity (even numbered items 2-18) and inattention (&quot;inattentiveness&quot;) (odd numbered items 1-17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behaviour as Assessed by Social Communication Questionnaire (SCQ)</measure>
    <time_frame>5.5 years (CA)</time_frame>
    <description>The SCQ is a brief instrument that helps evaluate communication skills and social functioning in children that can be used for screening for autism or autism spectrum disorders (ASD) in the general population. The score ranges from 0 to 39, with a cut off of greater than (&gt;) 15 indicating ASD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Pulmonary Morbidity</measure>
    <time_frame>6 months to 5 years (CA)</time_frame>
    <description>Pulmonary morbidity will be assessed with questions related to family history and smoking status as well as diagnosis of select pulmonary symptoms, conditions and related hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Assessment</measure>
    <time_frame>3 weeks to 5.5 years (CA)</time_frame>
    <description>Survival status will be assessed as the length of time from the participant's date of birth to death during the study due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) Assessed by the Pediatric Quality of Life Inventory (PedsQL™) Scales</measure>
    <time_frame>3 weeks to 5.5 years (CA)</time_frame>
    <description>HRQoL will be assessed via the validated Pediatric Quality of Life Inventory (PedsQL™) Scales appropriate for the child's age of development. The following scales will be used in this study: Infant Scale for ages 1-12 months (36 Items); Infant Scale for ages 13-24 months (45 Items); Toddler Scale for 2-4 years of age (21 Items); Young Child Scale for 5-7 years of age (23 Items). Scores are transformed to a 0 to 100 scale. Higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status Measured by the Health Status Classification System-Preschool (HSCS-PS)</measure>
    <time_frame>24 months to 5.5 years (CA)</time_frame>
    <description>HSCS-PS is a validated instrument adapted for use via parent proxy within the pediatric population age 2.5 - 5. The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility, Dexterity, Self-care, Emotion, Learn/remember, Think/problem solve, Pain, General Health, and Behavior) intended to provide a comprehensive assessment of a child's health status. The responses will be descriptively summarized as proportions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status Measured by the Health Utilities Index 2/3</measure>
    <time_frame>5 years (CA)</time_frame>
    <description>The Health Utilities Index (HUI) is a family of generic health profiles and preference-based systems used for measuring health status, reporting HRQoL, and producing utility scores. The HUI 2/3 system contains a number of attributes/domains to classify the level of health status. Each attribute or domain (eg, mobility, cognition, emotion or pain) is rated on a 5-point ordinal scale to indicate the severity level, ranging from 1-5 (higher numbers indicating a more severe level).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Participants who had short-term exposure to rhIGF-I/rhIGFBP-3 in previous study ROPP-2008-01 (NCT01096784)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Participants who received standard neonatal care in previous study ROPP-2008-01(NCT01096784)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants randomized in Study ROPP-2008-01, Section D are eligible to enroll in this
        study; completion of Study ROPP-2008-01 Section D is not required. Participants in Study
        ROPP-2008-01 are premature infants (gestational age of 23 weeks + 0 days to 27 weeks + 6
        days) who are randomized to receive either treatment with rhIGF-1/rhIGFBP-3 or standard
        neonatal care. Up to 121 participants were planned to be randomized in Study ROPP-2008-01
        Section D.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant was randomized in Study ROPP-2008-01, Section D

          2. Participants parent or legally authorized representative(s) must provide written
             informed consent prior to performing any study-related activities. Study-related
             activities are any procedures that would not have been performed during normal
             management of the participant.

        Exclusion Criteria:

          1. Any other condition or therapy that, in the Investigator's opinion, may pose a risk to
             the Participant or interfere with the participants ability to be compliant with this
             protocol or interfere with the interpretation of results

          2. The participant or participants parent or legally authorized representative(s) is
             unable to comply with the protocol as determined by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Weeks</minimum_age>
    <maximum_age>108 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>﻿00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznan</name>
      <address>
        <city>Poznań</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Peter's Hospital</name>
      <address>
        <city>Chertsey</city>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL EGA Institute for Women's Health</name>
      <address>
        <city>London</city>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

